Study looks at factor VIII products for hemophilia A

01/17/2013 | PhysiciansBriefing.com

The odds of inhibitory antibody development were the same for children with hemophilia A who took plasma-derived factor VIII products and those in the recombinant group, a Dutch study found. Researchers reported in the New England Journal of Medicine that inhibitor development risk was not linked with the von Willebrand factor content of these products or with switching between plasma-derived and recombinant.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN